Ex vivo allogeneic stimulation significantly improves expansion of cytokine-Induced killer cells without increasing their alloreactivity across HLA barriers

Maja Todorovic, Giulia Mesiano, Loretta Gammaitoni, Valeria Leuci, Lidia Giraudo Diego, Cristina Cammarata, Noela Jordaney, Fabrizio Carnevale-Schianca, Susanna Gallo, Franca Fagioli, Wanda Piacibello, Angela Rita Elia, Ymera Pignochino, Carmine Dell'Aglio, Giovanni Grignani, Alessandro Cignetti, Massimo Aglietta, Dario Sangiolo

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Cytokine-induced killer cells (CIKs) are ex vivo expanded T-NK lymphocytes capable of HLA-unrestricted antitumor activity. CIKs are promising candidates for adoptive cancer immunotherapies; they can be generated and infused in autologous settings of cancer patients, or from donors, after allogeneic hematopoietic cell transplant. Ex vivo expansion rates of CIKs are greatly variable among patients, with consequent potential clinical limitations for "poor expanders." We compared the standard expansion protocol with a new one, which included the timed addition of irradiated allogeneic peripheral blood mononuclear cells. Our hypothesis is that allogeneic stimulation might provide CIK cells with a proliferative boost and simultaneously decrease their alloreactivity versus third parties, if HLA-mismatched from the allogeneic stimulators. Allo-stimulated CIKs (AS-CIK) reached significantly higher expansion rates compared with standard controls, regardless if generated form healthy donors (131-vs. 32-fold) or cancer patients (117-vs. 14-fold). The expansion of the CD3+CD56+ subset was 2243-fold for AS-CIKs compared with 362 for standard CIKs. AS-CIKs efficiently killed osteosarcoma targets in vitro, results were comparable with that of standard CIKs. Standard and AS-CIKs did not show differences in phenotype and telomere length. The alloreactivity of AS-CIKs against third party HLA-mismatched peripheral blood mononuclear cells was reduced compared with standard CIKs (37% vs. 23%). In conclusion, alloreactivity of CIK cells may be exploited enhancing their final ex vivo expansion. In clinical perspective these findings may facilitate the extension of CIK-based immunotherapy to larger numbers of patients and, translated into hematopoietic cell transplant settings, contribute to reduce the risk of graft versus host disease in the hypothesis of infusions across HLA barriers.

Original languageEnglish
Pages (from-to)579-586
Number of pages8
JournalJournal of Immunotherapy
Volume35
Issue number7
DOIs
Publication statusPublished - Sep 2012

Fingerprint

Cytokine-Induced Killer Cells
Blood Cells
Tissue Donors
Transplants
Adoptive Immunotherapy
Neoplasms
Telomere
Graft vs Host Disease
Osteosarcoma
Immunotherapy
Lymphocytes
Phenotype

Keywords

  • CIK
  • donor lymphocytes infusion
  • immunotherapy

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Cancer Research
  • Pharmacology

Cite this

Ex vivo allogeneic stimulation significantly improves expansion of cytokine-Induced killer cells without increasing their alloreactivity across HLA barriers. / Todorovic, Maja; Mesiano, Giulia; Gammaitoni, Loretta; Leuci, Valeria; Giraudo Diego, Lidia; Cammarata, Cristina; Jordaney, Noela; Carnevale-Schianca, Fabrizio; Gallo, Susanna; Fagioli, Franca; Piacibello, Wanda; Elia, Angela Rita; Pignochino, Ymera; Dell'Aglio, Carmine; Grignani, Giovanni; Cignetti, Alessandro; Aglietta, Massimo; Sangiolo, Dario.

In: Journal of Immunotherapy, Vol. 35, No. 7, 09.2012, p. 579-586.

Research output: Contribution to journalArticle

Todorovic, Maja ; Mesiano, Giulia ; Gammaitoni, Loretta ; Leuci, Valeria ; Giraudo Diego, Lidia ; Cammarata, Cristina ; Jordaney, Noela ; Carnevale-Schianca, Fabrizio ; Gallo, Susanna ; Fagioli, Franca ; Piacibello, Wanda ; Elia, Angela Rita ; Pignochino, Ymera ; Dell'Aglio, Carmine ; Grignani, Giovanni ; Cignetti, Alessandro ; Aglietta, Massimo ; Sangiolo, Dario. / Ex vivo allogeneic stimulation significantly improves expansion of cytokine-Induced killer cells without increasing their alloreactivity across HLA barriers. In: Journal of Immunotherapy. 2012 ; Vol. 35, No. 7. pp. 579-586.
@article{f23a92bf1375461596c27592f8f31b96,
title = "Ex vivo allogeneic stimulation significantly improves expansion of cytokine-Induced killer cells without increasing their alloreactivity across HLA barriers",
abstract = "Cytokine-induced killer cells (CIKs) are ex vivo expanded T-NK lymphocytes capable of HLA-unrestricted antitumor activity. CIKs are promising candidates for adoptive cancer immunotherapies; they can be generated and infused in autologous settings of cancer patients, or from donors, after allogeneic hematopoietic cell transplant. Ex vivo expansion rates of CIKs are greatly variable among patients, with consequent potential clinical limitations for {"}poor expanders.{"} We compared the standard expansion protocol with a new one, which included the timed addition of irradiated allogeneic peripheral blood mononuclear cells. Our hypothesis is that allogeneic stimulation might provide CIK cells with a proliferative boost and simultaneously decrease their alloreactivity versus third parties, if HLA-mismatched from the allogeneic stimulators. Allo-stimulated CIKs (AS-CIK) reached significantly higher expansion rates compared with standard controls, regardless if generated form healthy donors (131-vs. 32-fold) or cancer patients (117-vs. 14-fold). The expansion of the CD3+CD56+ subset was 2243-fold for AS-CIKs compared with 362 for standard CIKs. AS-CIKs efficiently killed osteosarcoma targets in vitro, results were comparable with that of standard CIKs. Standard and AS-CIKs did not show differences in phenotype and telomere length. The alloreactivity of AS-CIKs against third party HLA-mismatched peripheral blood mononuclear cells was reduced compared with standard CIKs (37{\%} vs. 23{\%}). In conclusion, alloreactivity of CIK cells may be exploited enhancing their final ex vivo expansion. In clinical perspective these findings may facilitate the extension of CIK-based immunotherapy to larger numbers of patients and, translated into hematopoietic cell transplant settings, contribute to reduce the risk of graft versus host disease in the hypothesis of infusions across HLA barriers.",
keywords = "CIK, donor lymphocytes infusion, immunotherapy",
author = "Maja Todorovic and Giulia Mesiano and Loretta Gammaitoni and Valeria Leuci and {Giraudo Diego}, Lidia and Cristina Cammarata and Noela Jordaney and Fabrizio Carnevale-Schianca and Susanna Gallo and Franca Fagioli and Wanda Piacibello and Elia, {Angela Rita} and Ymera Pignochino and Carmine Dell'Aglio and Giovanni Grignani and Alessandro Cignetti and Massimo Aglietta and Dario Sangiolo",
year = "2012",
month = "9",
doi = "10.1097/CJI.0b013e31826b1fd9",
language = "English",
volume = "35",
pages = "579--586",
journal = "Journal of Immunotherapy",
issn = "1053-8550",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Ex vivo allogeneic stimulation significantly improves expansion of cytokine-Induced killer cells without increasing their alloreactivity across HLA barriers

AU - Todorovic, Maja

AU - Mesiano, Giulia

AU - Gammaitoni, Loretta

AU - Leuci, Valeria

AU - Giraudo Diego, Lidia

AU - Cammarata, Cristina

AU - Jordaney, Noela

AU - Carnevale-Schianca, Fabrizio

AU - Gallo, Susanna

AU - Fagioli, Franca

AU - Piacibello, Wanda

AU - Elia, Angela Rita

AU - Pignochino, Ymera

AU - Dell'Aglio, Carmine

AU - Grignani, Giovanni

AU - Cignetti, Alessandro

AU - Aglietta, Massimo

AU - Sangiolo, Dario

PY - 2012/9

Y1 - 2012/9

N2 - Cytokine-induced killer cells (CIKs) are ex vivo expanded T-NK lymphocytes capable of HLA-unrestricted antitumor activity. CIKs are promising candidates for adoptive cancer immunotherapies; they can be generated and infused in autologous settings of cancer patients, or from donors, after allogeneic hematopoietic cell transplant. Ex vivo expansion rates of CIKs are greatly variable among patients, with consequent potential clinical limitations for "poor expanders." We compared the standard expansion protocol with a new one, which included the timed addition of irradiated allogeneic peripheral blood mononuclear cells. Our hypothesis is that allogeneic stimulation might provide CIK cells with a proliferative boost and simultaneously decrease their alloreactivity versus third parties, if HLA-mismatched from the allogeneic stimulators. Allo-stimulated CIKs (AS-CIK) reached significantly higher expansion rates compared with standard controls, regardless if generated form healthy donors (131-vs. 32-fold) or cancer patients (117-vs. 14-fold). The expansion of the CD3+CD56+ subset was 2243-fold for AS-CIKs compared with 362 for standard CIKs. AS-CIKs efficiently killed osteosarcoma targets in vitro, results were comparable with that of standard CIKs. Standard and AS-CIKs did not show differences in phenotype and telomere length. The alloreactivity of AS-CIKs against third party HLA-mismatched peripheral blood mononuclear cells was reduced compared with standard CIKs (37% vs. 23%). In conclusion, alloreactivity of CIK cells may be exploited enhancing their final ex vivo expansion. In clinical perspective these findings may facilitate the extension of CIK-based immunotherapy to larger numbers of patients and, translated into hematopoietic cell transplant settings, contribute to reduce the risk of graft versus host disease in the hypothesis of infusions across HLA barriers.

AB - Cytokine-induced killer cells (CIKs) are ex vivo expanded T-NK lymphocytes capable of HLA-unrestricted antitumor activity. CIKs are promising candidates for adoptive cancer immunotherapies; they can be generated and infused in autologous settings of cancer patients, or from donors, after allogeneic hematopoietic cell transplant. Ex vivo expansion rates of CIKs are greatly variable among patients, with consequent potential clinical limitations for "poor expanders." We compared the standard expansion protocol with a new one, which included the timed addition of irradiated allogeneic peripheral blood mononuclear cells. Our hypothesis is that allogeneic stimulation might provide CIK cells with a proliferative boost and simultaneously decrease their alloreactivity versus third parties, if HLA-mismatched from the allogeneic stimulators. Allo-stimulated CIKs (AS-CIK) reached significantly higher expansion rates compared with standard controls, regardless if generated form healthy donors (131-vs. 32-fold) or cancer patients (117-vs. 14-fold). The expansion of the CD3+CD56+ subset was 2243-fold for AS-CIKs compared with 362 for standard CIKs. AS-CIKs efficiently killed osteosarcoma targets in vitro, results were comparable with that of standard CIKs. Standard and AS-CIKs did not show differences in phenotype and telomere length. The alloreactivity of AS-CIKs against third party HLA-mismatched peripheral blood mononuclear cells was reduced compared with standard CIKs (37% vs. 23%). In conclusion, alloreactivity of CIK cells may be exploited enhancing their final ex vivo expansion. In clinical perspective these findings may facilitate the extension of CIK-based immunotherapy to larger numbers of patients and, translated into hematopoietic cell transplant settings, contribute to reduce the risk of graft versus host disease in the hypothesis of infusions across HLA barriers.

KW - CIK

KW - donor lymphocytes infusion

KW - immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=84865480017&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865480017&partnerID=8YFLogxK

U2 - 10.1097/CJI.0b013e31826b1fd9

DO - 10.1097/CJI.0b013e31826b1fd9

M3 - Article

C2 - 22892454

AN - SCOPUS:84865480017

VL - 35

SP - 579

EP - 586

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

SN - 1053-8550

IS - 7

ER -